Duchenne muscular dystrophy (DMD) has significant medical applications. It primarily affects muscle function due to a lack of dystrophin protein, causing progressive weakness and limited mobility. Key features of duchenne muscular dystrophy include genetic origins and early onset in childhood. DMD's impact encompasses reduced muscle strength, mobility challenges, and cardiac involvement. Despite its challenges, therapies, and interventions aim to slow progression, improve quality of life, and enhance muscle function. The condition's comprehensive understanding guides research and treatments to alleviate its effects.
According to Data Bridge Market Research, the Global Duchenne Muscular Dystrophy Market accounted for USD 693.34 million in 2021 and is expected to reach USD 1,753.82 million by 2029. The market is expected to grow with a CAGR of 12.3% in the forecast period of 2022 to 2029.
“Heightened corticosteroid utilization boosts the market’s growth”
The duchenne muscular dystrophy (DMD) market experiences growth due to heightened corticosteroid utilization. Corticosteroids, such as prednisone and deflazacort, are prominent treatments for DMD, aiding muscle strength and delaying disease progression. Their increased use reflects their effectiveness in managing symptoms and enhancing patients' quality of life. As awareness grows and more patients are diagnosed, the demand for such treatments rises, contributing to the expansion of the DMD market, which focuses on improving the well-being of those affected by this genetic disorder
What restraints the growth of the global duchenne muscular dystrophy market?
“Lack of awareness restraints the market’s growth”
The growth of the duchenne muscular dystrophy (DMD) market faces limitations due to a lack of awareness. Insufficient public and medical community awareness about DMD's symptoms, diagnosis, and available treatments delays timely interventions. This leads to underdiagnoses and reduced treatment initiation. Greater awareness campaigns are vital to educate the public, healthcare professionals, and policymakers, ensuring early diagnosis, access to therapies, and supportive care.
Segmentation: Global Duchenne Muscular Dystrophy Market
The global duchenne muscular dystrophy market is segmented on the basis of therapy, treatment type, route of administration, distribution channel, and end-user.
- On the basis of therapy, the duchenne muscular dystrophy market is segmented into mutation suppression and exon skipping approach.
- On the basis of treatment type, the duchenne muscular dystrophy market is segmented into molecular-based therapies, steroid therapy, others.
- On the basis of route of administration, the duchenne muscular dystrophy market is segmented into oral, parenteral, others.
- On the basis of distribution channel, the duchenne muscular dystrophy market is segmented into hospital pharmacy, online pharmacy, retail pharmacy.
- On the basis of end-user, the duchenne muscular dystrophy market is segmented into hospitals, homecare, specialty clinics, others.
Regional Insights: North America dominates the Global Duchenne Muscular Dystrophy Market
North America dominates the market due to a rise in myelofibrosis (MF) cases, coupled with a high demand for targeted therapies and advanced healthcare facilities, which drives the market growth. As MF becomes more prevalent, the need for effective treatments grows. This, combined with the demand for modern healthcare resources, propels the expansion of the market.
Asia-Pacific has been witnessing positive growth for the global duchenne muscular dystrophy market throughout the forecasted period due to the confluence of heightened disease awareness and rapidly growing disposable income has fueled the growth of the market. Greater public knowledge about diseases, coupled with increased financial resources, has led to heightened demand for advanced healthcare solutions and treatments, driving the expansion of the market.
Recent Developments
- In September 2022, In a collaborative study involving the University of Portsmouth, I-STEM, CNRS, the Maj Institute of Pharmacology of the Polish Academy of Sciences, and AFM in France, researchers discovered that Duchenne muscular dystrophy (DMD) initiates at an earlier stage within cells designated to develop into muscle fibers, referred to as myoblasts.
- In September 2022, The research revealed that Eteplirsen demonstrates effectiveness in postponing pulmonary decline among individuals diagnosed with Duchenne muscular dystrophy (DMD).
- In September 2022, A team of researchers from Johns Hopkins Medicine identified that an experimental drug, initially designed to treat kidney disease patients, extends survival and enhances muscle function in mice with a severe form of Duchenne muscular dystrophy (DMD) through genetic engineering.
To know more about the study visit, https://www.databridgemarketresearch.com/pt/reports/global-duchenne-muscular-dystrophy-market
The Prominent Key Players Operating in the Global Duchenne Muscular Dystrophy Market Include:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hikma Pharmaceuticals PLC (U.K.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bristol Myers Squibb Company (U.S.)
- GSK Plc. (U.K.)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd (India)
- Boehringer Ingelheim International Gmbh (Germany)
- Sanofi (France)
- Sarepta Therapeutics, Inc (U.K.)
- FibroGen, Inc. (U.S.)
Above are the key players covered in the report, to know about more and exhaustive list of global duchenne muscular dystrophy market companies contact, https://www.databridgemarketresearch.com/pt/contact
Research Methodology: Global Duchenne Muscular Dystrophy Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
